Table 1.
Inclusion criteria for papers: - Describing development, validation or updating of a DSS; - Describing DSS that aims to predict prognosis (overall survival or progression-free survival), optimal treatment selection or toxicity; - Describing DSS that is depicted either as a risk score with a formula, nomogram, decision tree or (online) calculator or application. - Describing DSS that is applied in incurable patients with (initial or recurrent) metastatic NSCLC (stages IIIB and IV). - Describing DSS that is developed or validated in clinical data collected after 2000, as older data would not correctly reflect the current clinical practices anymore; - Papers published in English. |
Exclusion criteria for papers: - Examining early stage NSCLC patients or patients with oligometastases; - Comparing treatments with curative intention or predicting whether curing metastases is still possible; - Describing univariate or multivariate analyses where only Hazard ratios or Odds ratios are reported, but no calculation of survival time for individual patients; - Non-original papers (e.g., reviews, methodological papers) only used for reference tracking; - Describing separate parameters that cannot be applied as an independent DSS; - Describing general tools that are not developed or validated in stage IIIB/IV NSCLC. |